PEG-IFNα

Phase 3Biologic

Gilead

PEG-IFNα is one of 105 biologic programs targeting Combination Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Combination TherapyActive, not recruiting

Chronic HepatitisCompleted

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic Hepatitis BRecruiting

Combination TherapyPhase 2

Active, not recruiting

Chronic HepatitisPhase 3

Completed

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Chronic Hepatitis BPhase 3

Recruiting

Competition

Competitive Landscape

81 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Phase 3

43 2

Bepirovirsen

GSK

Phase 3

1 3

Opdivo

Bristol-Myers Squibb

Phase 2

2 4

PEG-IFNα

Gilead

Phase 3

12 5

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 6

Pegylated Interferon Alfa

Merck & Co.

Phase 3

4 7

NA Therapy

GSK

Phase 3

2 8

AHB-137

AAusper Biopharma Co., Ltd.

Phase 3

3 9

Azvudine

HHenan Genuine Biotech Co., Ltd.

Phase 3

1 10

Brelovitug

MMirum Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Chronic Hepatitis B

NCT05771402

ApprovedRecruiting

Chronic Hepatitis B

NCT07573943

Q1 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06425341

Q2 2027

Phase 2Active, not recruiting

Chronic Hepatitis

NCT06491563

Q3 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06650852

Clinical

Trials by Indication[1]

Chronic Hepatitis12 trials

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT06491563·150 enrolled

Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

Recruiting·MMinghui Li··NCT06696664·120 enrolled

The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia

Unknown status·—··NCT05357235·1,200 enrolled

Show 9 more trials

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT06425341·369 enrolled

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed· Roche logo

Roche·Phase 2·NCT04225715·281 enrolled

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01405560·42 enrolled

The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia

Unknown status·—··NCT05357183·1,200 enrolled

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Completed·VVir Biotechnology, Inc.·Phase 1/2·NCT05612581·33 enrolled

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Completed· Gilead logo

Gilead·Phase 4·NCT01277601·751 enrolled

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01405937·51 enrolled

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01370642·294 enrolled

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

Chronic Hepatitis b3 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·120 enrolled

A Randomized, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs)

Recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07069569·200 enrolled

HCV Infection2 trials

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT01962441·601 enrolled

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Completed· Gilead logo

Gilead·Phase 3·NCT01625338·534 enrolled

Chronic Hepatitis B Virus Infection2 trials

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Terminated·AAssembly Biosciences·Phase 2·NCT04781647·54 enrolled

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT04856085·244 enrolled

Acute Myeloid Leukemia1 trial

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02328755·37 enrolled

4 more indications

Efficacy and Safety1 trial

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01826981·359 enrolled

Combination Therapy1 trial

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT05970289·86 enrolled

Fibrosis1 trial

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Completed·—·Phase 4·NCT01938781·400 enrolled

Effectiveness1 trial

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Completed·—·N/A·NCT02113631·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for PEG-IFNα. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-IFNα compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-IFNα. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Gilead

PEG-IFNα

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Hepatitis12 trials

Chronic Hepatitis b3 trials

HCV Infection2 trials

Chronic Hepatitis B Virus Infection2 trials

Acute Myeloid Leukemia1 trial

Efficacy and Safety1 trial

Combination Therapy1 trial

Fibrosis1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News